Patent application number | Description | Published |
20100168015 | PEPTIDES WITH CAPACITY FOR BINDING WITH INTERLEUKINE 10 (IL-10) - The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions. | 07-01-2010 |
20100267623 | PEPTIDES WITH CAPACITY TO BIND TO SCURFIN AND APPLICATIONS - The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X | 10-21-2010 |
20110027224 | USE OF A CYTOKINE FROM THE INTERLEUKIN-6 FAMILY IN THE PREPARATION OF A COMPOSITION FOR COMBINED ADMINISTRATION WITH INTERFERON-ALPHA - The invention relates to the use of at least one cytokine from the IL-6 family −gp130, preferably selected from among IL-11, the leukaemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1, ciliary neurotrophic factor (CNTF), the cardiotrophin-like cytokine (CLC) and combinations thereof or a DNA sequence encoding same, in the preparation of a pharmaceutical composition which is intended for combined administration with at least one IFN-α or a DNA sequence encoding same, for use in the treatment of viral diseases. The invention also relates to a pharmaceutical composition comprising a pharmaceutically-acceptable quantity of at least one cytokin from the IL-6 family −gp130 or a DNA sequence encoding same and a pharmaceutically-acceptable quantity of at least one IFN-α or a DNA sequence encoding same, a pharmaceutical kit and a method for the treatment of viral diseases with the combined administration of the aforementioned cytokines and IFN-α. | 02-03-2011 |
20130064790 | PEPTIDES WITH THE CAPACITY TO BIND TO INTERLEUKIN-10 (IL-10) - The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions. | 03-14-2013 |
Patent application number | Description | Published |
20110076304 | ADAPTER MOLECULE FOR THE DELIVERY OF ADENOVIRUS VECTORS - The invention relates to an adapter protein comprising a coxackievirus and adenovirus receptor (CAR) region and a human CD40 ligand and to the uses thereof for promoting adenoviral transduction of dendritic cells while at the same time promoting maturation of the DCs. The invention also relates to pharmaceutical compositions comprising said adapter protein and an adenovirus encoding an antigen and the uses thereof in a method for eliciting an immune response against the antigen encoded in said adenovirus as well as to antigen-loaded dendritic cells obtained the adaptor protein and an adenovirus and to the uses thereof in a method of eliciting an immune response against the antigen encoded in the adenovirus. | 03-31-2011 |
20110081718 | SYSTEM FOR PACKAGING HIGH-CAPACITY ADENOVIRUSES - The invention relates to a nuew system for production and packaging of high capacity adenoviral vectors which does not require the use of helper virues and which is characterized in that it integrates the adenoviral genes needed for the control, replication and packaging of the viral particuiles in the genome of a host cell, which results in the improvement of the long term stability of the production system. | 04-07-2011 |
20110293562 | USE OF CARDIOTROPHIN-1 FOR THE TREATMENT OF METABOLIC DISEASES - The invention is related to the use of cardiotrophin-1 (CT-1) for the treatment of obesity and associated disorders: hyperglycaemias, insulin resistance, development of type 2 diabetes and dyslipemias and given its anorexigenic role, fat oxidation stimulant, hypoglycaemic, sensitizing agent of the action of insulin on a skeletal muscle level and inhibitor of the intestinal transport of glucose by enterocytes. | 12-01-2011 |
20120308517 | COMPOSITIONS FOR THE TREATMENT OF INFECTIOUS AND TUMOURAL DISEASES - The present invention relates to the use of compositions comprising a type III interferon and oncostatin M and to the use of said compositions for the treatment and prevention of infectious and neoplastic diseases. | 12-06-2012 |
Patent application number | Description | Published |
20110081718 | SYSTEM FOR PACKAGING HIGH-CAPACITY ADENOVIRUSES - The invention relates to a nuew system for production and packaging of high capacity adenoviral vectors which does not require the use of helper virues and which is characterized in that it integrates the adenoviral genes needed for the control, replication and packaging of the viral particuiles in the genome of a host cell, which results in the improvement of the long term stability of the production system. | 04-07-2011 |
20110268757 | USE OF PHENOL-SOLUBLE MODULINS FOR VACCINE DEVELOPMENT - The invention relates to methods for increasing immunogenicity of an antigenic peptide by means of its covalent coupling to a modulin derived peptide (PSM, phenol soluble modulin). In particular, the binding of PSMα, PSMγ and PSMδ peptides to an antigen (from a pathogen or a tumor associated protein) increases the capacity of the antigen to activate an immune response in vivo. Thus, the PSMα, PSMγ and PSMδ peptides bound to these antigens may be used in the development of vaccines for preventing or treating infectious diseases or cancer | 11-03-2011 |
20120225933 | REGULATED EXPRESSION SYSTEMS - The application relates to gene constructs for inducible hepato-specific expression of polynucleotides of interest in response to an inducer agent, said constructs comprising (i) an inducible bi-directional operator-promoter with at least one responsive element to said inducer agent flanked by two hepato-specific promoters acting in divergent manner, (ii) a first nucleotide sequence encoding a transactivator which may be activated by said inducer agent operatively coupled to the first hepato-specific promoter and (iii) a second nucleotide sequence operatively coupled to the second hepato-specific promoter, wherein the promoters are induced as a consequence of the binding of the transactivator to the operator region of the operator-promoter in the presence of the inducer agent. | 09-06-2012 |